MBX Biosciences, Inc. MBX
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- +57.10%
- 1 year
- +83.31%
5D -0.88 (-1.62%)
- Market cap
- 2.46B
- EPS (ttm)
- -3.03
- Shares out
- 49.66M
- Forward P/E
- -11.38
- YTD return
- +57.10%
- 1-year return
- +83.31%
- 50-day average
- 55.07
- 200-day average
- 46.62
- Enterprise value
- 2.17B
- Price / book
- 5.20
- Volume
- 579.61K
- Avg volume
- 531.00K
- Open
- 52.92
- Previous close
- 53.41
- Day's range
- 49.36 – 54.43
- 52-week range
- 26.00 – 72.64
- Beta
- 0.18
- Analysts
- Strong Buy
- Price target
- 95.09 (+91.9%)
- Earnings date
- Mar 11, 2027
Key statistics
- Free cash flow
- -54.00M
- Total cash
- 481.59M
- Total debt
- 3.29M
- Return on equity
- -33.72%
- Short % of float
- 11.92%
Fundamental scorecard
3 of 25 checks passed on MBX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 80.00
- Target (mean)
- 95.09
- Target (high)
- 150.00
- Strong buy3
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 11, 2027
Expected Mar 11, 2027. Consensus EPS estimate -0.84465.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 11, 2027 | Dec 30, 2026 | -0.95 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.82675 | -1.29 | -0.46 | -56.03% |
| Aug 6, 2026 | Jun 30, 2026 | -0.63251 | -0.78 | -0.15 | -23.32% |
| May 7, 2026 | Mar 31, 2026 | -0.62 | -0.51 | +0.11 | +17.74% |
| Mar 12, 2026 | Dec 31, 2025 | -0.64 | -0.49 | +0.15 | +23.44% |
| Nov 6, 2025 | Sep 30, 2025 | -0.73 | -0.63 | +0.10 | +13.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2026 | HC Wainwright & Co. | init | — | Buy |
| Oct 12, 2026 | Stifel | main | Buy | Buy |
| Oct 2, 2026 | Guggenheim | main | Buy | Buy |
| Aug 10, 2026 | Truist Securities | main | Buy | Buy |
| Jul 29, 2026 | Mizuho | main | Outperform | Outperform |
| May 12, 2026 | Barclays | main | Overweight | Overweight |
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mbxbio.com
News
Your note
Sign in to keep a note on MBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AZOULAY SALOMON M.D. | Officer | Sale | Nov 3, 2026 | 14,026 |
| BARTRAM RICHARD B | Chief Financial Officer | Stock Award(Grant) | Feb 1, 2026 | 15,000 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 17, 2025 | 0 |
| HAWRYLUK P KENT | Chief Executive Officer | Sale | May 5, 2026 | 1,214,440 |
| HERON PATRICK J | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 25, 2025 | 0 |
| HOERTER STEVEN L | Chief Executive Officer | Sale | Nov 9, 2026 | 98,045 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.84% | 7,368,420 | 365.11M | Sep 29, 2026 |
| Frazier Life Sciences Management, L.P. | 13.40% | 6,652,013 | 329.61M | Sep 29, 2026 |
| Wellington Management Group, LLP | 10.40% | 5,164,535 | 255.90M | Sep 29, 2026 |
| Paradigm Biocapital Advisors LP | 7.60% | 3,772,885 | 186.95M | Sep 29, 2026 |
| NEA Management Company, LLC | 7.28% | 3,614,486 | 179.10M | Sep 29, 2026 |
| Blackrock Inc. | 6.99% | 3,473,447 | 172.11M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.29% | 1,135,375 | 56.26M | Jun 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.76% | 873,492 | 43.28M | Jun 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.65% | 817,600 | 40.51M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.62% | 805,557 | 39.92M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.41% | 700,000 | 34.68M | Sep 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.36% | 674,700 | 33.43M | Aug 30, 2026 |
